Ian Hodgson Biography and Net Worth

Dr. Ian Hodgson has served as our Chief Operating Officer since March 15th, 2025. Dr. Hodgson has over 25 years of experience in drug development and operations across biotech, large pharmaceutical companies and contract research organizations.

Dr. Hodgson joined Corbus International Ltd. in October 2022 as Head of Clinical and European Operations and transitioned to Head of Operations in March of 2024. Since May 2021, Dr. Hodgson has served as a non-executive director and board advisor for MD Group Ltd., a privately owned patient services company, and Skyelarke, a health-tech company specializing in delivering patient payments in clinical trials. Previously, he held several leadership positions, including Vice President, Head of Clinical Services at TMC Pharma Services Ltd., a rare disease consultancy from September 2021 through September 2022, Vice President, Clinical Development – Rare Diseases at Syneos Health from November 2020 through September 2021, and Head of Clinical Operations at Mereo Biopharma from 2015 through 2020.

Dr. Hodgson earned a PhD in Medical Microbiology from Queen Margaret University in collaboration with the University of Edinburgh (awarded by the Open University) and a BSc (Hons) in Food Technology from Reading University.

What is Ian Hodgson's net worth?: The estimated net worth of Ian Hodgson is at least $472.80 thousand as of February 3rd, 2026. Hodgson owns 51,927 shares of Corbus Pharmaceuticals stock worth more than $472,795 as of July 27th. This net worth estimate does not reflect any other investments that Hodgson may own. Learn More about Ian Hodgson's net worth.
How do I contact Ian Hodgson?: The corporate mailing address for Hodgson and other Corbus Pharmaceuticals executives is 500 River Ridge Drive, Norwood MA, 02062. Corbus Pharmaceuticals can also be reached via phone at (617) 963-0100 and via email at [email protected]. Learn More on Ian Hodgson's contact information.
Has Ian Hodgson been buying or selling shares of Corbus Pharmaceuticals?: Ian Hodgson has not been actively trading shares of Corbus Pharmaceuticals during the last ninety days. Most recently, Ian Hodgson sold 2,415 shares of the business's stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $8.09, for a transaction totalling $19,537.35. Following the completion of the sale, the chief operating officer now directly owns 51,927 shares of the company's stock, valued at $420,089.43. Learn More on Ian Hodgson's trading history.
Who are Corbus Pharmaceuticals' active insiders?: Corbus Pharmaceuticals' insider roster includes Anne Altmeyer (Director), Yuval Cohen (CEO), Ian Hodgson (COO), John Jenkins (Director), and Winston Kung (Director). Learn More on Corbus Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Corbus Pharmaceuticals?: During the last twelve months, Corbus Pharmaceuticals insiders bought shares 2 times. They purchased a total of 13,500 shares worth more than $101,205.00. During the last twelve months, insiders at the biopharmaceutical company sold shares 10 times. They sold a total of 86,641 shares worth more than $1,177,188.36. The most recent insider tranaction occured on June, 10th when Director Winston Kung sold 2,026 shares worth more than $16,025.66. Insiders at Corbus Pharmaceuticals own 3.5% of the company. Learn More about insider trades at Corbus Pharmaceuticals.
Information on this page was last updated on 6/10/2026.

Ian Hodgson Insider Trading History at Corbus Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/3/2026	Sell	2,415	$8.09	$19,537.35	51,927

Ian Hodgson Buying and Selling Activity at Corbus Pharmaceuticals

Corbus Pharmaceuticals Company Overview

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Today's Range

Now: $9.21

$9.05

$9.54

50 Day Range

MA: $8.75

$7.38

$11.51

2 Week Range

Now: $9.21

$7.12

$20.56

Volume

313,231 shs

Average Volume

333,052 shs

Market Capitalization

$170.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.55